Restoring Glycemic Control in Type 2 Diabetes through Fiber-Induced Microbial Remodeling
DOI:
https://doi.org/10.71222/9h0q7h53Keywords:
type 2 diabetes, dietary intervention, gut microbiota, glucose homeostasis, chronic disease managementAbstract
Dietary composition plays a vital role in the intervention and management of chronic metabolic diseases. This study evaluated the effects of a high-fiber diet on gut microbiota and glucose regulation in patients with type 2 diabetes through a rigorously designed clinical intervention trial. Participants in the intervention group followed a personalized high-fiber diet continuously for 12 weeks. The results showed a 16.8% reduction in fasting blood glucose and a 1.4% decrease in glycated hemoglobin (HbA1c). Additionally, the relative abundance of beneficial gut bacteria, such as Bifidobacterium, significantly increased. These findings indicate that a high-fiber diet can improve glucose metabolism by altering the composition of the gut microbiota. The study provides solid scientific evidence to support the refinement of nutritional strategies for diabetes management.
References
1. Y. Zheng, S. H. Ley, and F. B. Hu, "Global aetiology and epidemiology of type 2 diabetes mellitus and its complications," Nat. Rev. Endocrinol., vol. 14, no. 2, pp. 88-98, 2018, doi: 10.1021/ar3001525.
2. H. Wang, G. Zhang, Y. Zhao, F. Lai, W. Cui, J. Xue, et al., "Rpf-eld: Regional prior fusion using early and late distillation for breast cancer recognition in ultrasound images," in Proc. 2024 IEEE Int. Conf. Bioinformatics Biomedicine (BIBM), Dec. 2024, pp. 2605-2612, doi: 10.1109/BIBM62325.2024.10821972.
3. H. Qiu, S. Cao, and R. Xu, "Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020," Cancer Commun., vol. 41, no. 10, pp. 1037-1048, 2021, doi: 10.1002/cac2.12197.
4. J. Yin, X. Wu, and X. Liu, "Multi-class classification of breast cancer gene expression using PCA and XGBoost," in Proc. 4th Int. Conf. Biol. Eng. Med. Sci., 2024, doi: 10.20944/preprints202410.1775.v1.
5. L. Wang, et al., "Prevalence and treatment of diabetes in China, 2013-2018," JAMA, vol. 326, no. 24, pp. 2498-2506, 2021, doi:10.1001/jama.2021.22208.
6. Y. Wang, Y. Wen, X. Wu, L. Wang, and H. Cai, "Assessing the Role of Adaptive Digital Platforms in Personalized Nutrition and Chronic Disease Management," World J. Innov. Mod. Technol., vol. 8, no. 1, 2025, doi: 10.53469/wjimt.2025.08(01).05.
7. M. Lotfy, J. Adeghate, H. Kalasz, J. Singh, and E. Adeghate, "Chronic complications of diabetes mellitus: a mini review," Curr. Diabetes Rev., vol. 13, no. 1, pp. 3-10, 2017, doi: 10.2174/1573399812666151016101622.
8. X. Shi, Y. Tao, and S. C. Lin, "Deep neural network-based prediction of B-cell epitopes for SARS-CoV and SARS-CoV-2: En-hancing vaccine design through machine learning," in Proc. 2024 4th Int. Signal Process., Communications Eng. Manag. Conf. (ISPCEM), Nov. 2024, pp. 259-263, doi: 10.1109/ISPCEM64498.2024.00050.
9. M. Lind, H. Imberg, R. L. Coleman, O. Nerman, and R. R. Holman, "Historical HbA1c values may explain the type 2 diabetes legacy effect: UKPDS 88," Diabetes Care, vol. 44, no. 10, pp. 2231-2237, 2021, doi: 10.2337/dc20-2439.
10. Y. Wang, Y. Wen, X. Wu, and H. Cai, "Comprehensive Evaluation of GLP1 Receptor Agonists in Modulating Inflammatory Pathways and Gut Microbiota," World J. Innov. Mod. Technol., vol. 7, no. 5, 2024, doi: 10.53469/wjimt.2024.07(06).23.
11. J. Nadhiya, M. K. Vijayalakshmi, and S. Showbharnikhaa, "A brief review on diabetes mellitus," J. Pharma Insights Res., vol. 2, no. 1, pp. 117–121, 2024, doi: 10.5281/zenodo.10631511.
12. W. Bielka, A. Przezak, and A. Pawlik, "The role of the gut microbiota in the pathogenesis of diabetes," Int. J. Mol. Sci., vol. 23, no. 1, p. 480, 2022, doi: 10.3390/ijms23010480.
13. T. Zhang, B. Zhang, F. Zhao, and S. Zhang, "COVID-19 localization and recognition on chest radiographs based on Yolov5 and EfficientNet," in Proc. 2022 7th Int. Conf. Intell. Comput. Signal Process. (ICSP), Apr. 2022, pp. 1827–1830, doi: 10.1109/ICSP54964.2022.9778327.
14. M. Sedighi, et al. "Comparison of gut microbiota in adult patients with type 2 diabetes and healthy individuals," Microb. Pathog., vol. 111, pp. 362–369, 2017, doi: 10.1016/j.micpath.2017.08.038.
15. H. Ziang, J. Zhang, and L. Li, "Framework for lung CT image segmentation based on UNet++," arXiv preprint, arXiv:2501.02428, 2025, doi: 10.48550/arXiv.2501.02428.
16. V. Vinelli, et al., "Effects of dietary fibers on short-chain fatty acids and gut microbiota composition in healthy adults: a sys-tematic review," Nutrients, vol. 14, no. 13, p. 2559, 2022, doi: 10.3390/nu14132559.
17. Y. Deng, W. Cui, and X. Liu, "Head Tumor Segmentation and Detection Based on ResUNet," in Proc. 5th Int. Conf. Signal Pro-cess. Mach. Learn., 2024, doi: 10.54254/2755-2721/99/20251810.
18. K. H. Allin, T. Nielsen, and O. Pedersen, "Mechanisms in endocrinology: gut microbiota in patients with type 2 diabetes mellitus," Eur. J. Endocrinol., vol. 172, no. 4, pp. R167–R177, 2015, doi: 10.1530/EJE-14-0874.
19. H. Wang, Y. Wen, X. Wu, L. Wang, and H. Cai, "Modulation of Gut Microbiota and Glucose Homeostasis through High-Fiber Dietary Intervention in Type 2 Diabetes Management," World J. Innov. Mod. Technol., vol. 7, no. 5, 2024, doi: 10.53469/wjimt.2024.07(06).04.
20. J. B. Qiao, et al., "Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis," J. Control. Release, vol. 283, pp. 113–125, 2018, doi: 10.1016/j.jconrel.2018.05.032.
21. E. Bezirtzoglou, et al., "Maintaining digestive health in diabetes: the role of the gut microbiome and the challenge of functional foods," Microorganisms, vol. 9, no. 3, p. 516, 2021, doi: 10.3390/microorganisms9030516.
22. Y. Wang, L. Wang, Y. Wen, X. Wu, and H. Cai, "Precision-Engineered Nanocarriers for Targeted Treatment of Liver Fibrosis and Vascular Disorders," World J. Innov. Mod. Technol., vol. 8, no. 1, 2025, doi: 10.53469/wjimt.2025.08(01).07.
23. G. Qu, et al., "Self-assembled micelles based on N-octyl-N’-phthalyl-O-phosphoryl chitosan derivative as an effective oral carrier of paclitaxel," Carbohydr. Polym., vol. 207, pp. 428–439, 2019, doi: 10.1016/j.carbpol.2018.11.099.
24. A. E. Juhasz, et al., "Galactomannans are the most effective soluble dietary fibers in type 2 diabetes: a systematic review and network meta-analysis," Am. J. Clin. Nutr., vol. 117, no. 2, pp. 266–277, 2023, doi: 10.1016/j.ajcnut.2022.12.015.
25. J. Zhu, et al., "Multimodal nanoimmunotherapy engages neutrophils to eliminate Staphylococcus aureus infections," Nat. Nanotechnol., pp. 1–12, 2024, doi: 10.1038/s41565-024-01648-8.
26. Y. Wen, X. Wu, L. Wang, H. Cai, and Y. Wang, "Application of Nanocarrier-Based Targeted Drug Delivery in the Treatment of Liver Fibrosis and Vascular Diseases," J. Med. Life Sci., vol. 1, no. 2, pp. 63–69, 2025, doi: 10.71222/bc9c9s73.
27. J. Chen, J. He, R. P. Wildman, K. Reynolds, R. H. Streiffer, and P. K. Whelton, "A randomized controlled trial of dietary fiber intake on serum lipids," Eur. J. Clin. Nutr., vol. 60, no. 1, pp. 62–68, 2006, doi: 10.1038/sj.ejcn.1602268.
28. I. K. Lee, R. Xie, A. Luz-Madrigal, S. Min, J. Zhu, J. Jin, et al., "Micromolded honeycomb scaffold design to support the generation of a bilayered RPE and photoreceptor cell construct," Bioact. Mater., vol. 30, pp. 142–153, 2023, doi: 10.1016/j.bioactmat.2023.07.019.
29. N. Yodsanit, et al., "Targeted PERK inhibition with biomimetic nanoclusters confers preventative and interventional benefits to elastase-induced abdominal aortic aneurysms," Bioact. Mater., vol. 26, pp. 52–63, 2023, doi: 10.1016/j.bioactmat.2023.02.009.
30. M. H. Bhat, Y. A. Hajam, Neelam, R. Kumar, and Diksha, "Microbial Diversity and Their Role in Human Health and Diseases," in Role of Microbes in Sustainable Development: Human Health and Diseases, Singapore: Springer Nature Singapore, 2023, pp. 1–33. ISBN: 9789819931262.
31. Y. Wang, Y. Wen, X. Wu, and H. Cai, "Application of Ultrasonic Treatment to Enhance Antioxidant Activity in Leafy Vegeta-bles," Int. J. Adv. Appl. Sci. Res., vol. 3, pp. 49–58, 2024, doi: 10.5281/zenodo.14275691.
32. C. Chaiyasut, et al., "Influence of Bifidobacterium breve on the glycaemic control, lipid profile and microbiome of type 2 diabetic subjects: a preliminary randomized clinical trial," Pharmaceuticals, vol. 16, no. 5, p. 695, 2023, doi: 10.3390/ph16050695.
33. Y. Wang, M. Shen, L. Wang, Y. Wen, and H. Cai, "Comparative Modulation of Immune Responses and Inflammation by n-6 and n-3 Polyunsaturated Fatty Acids in Oxylipin-Mediated Pathways," World J. Innov. Mod. Technol., vol. 7, no. 4, 2024, doi: 10.53469/wjimt.2024.07(05).17.
34. F. Z. Marques, et al., "High-fiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice," Circulation, vol. 135, no. 10, pp. 964–977, 2017, doi: 10.1161/CIRCULATIONAHA.116.024545.
